source Post navigation SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes – TCTMD.com Poxel Announces Grant of New Patent in Japan for the Use of Imeglimin in Type-2 Diabetic Patients with Renal Impairment – Business Wire